Trademark: 88141769
Word
CHOLESTOSOMES
Status
Dead
Status Code
606
Status Date
Monday, June 6, 2022
Serial Number
88141769
Mark Type
4000
Filing Date
Wednesday, October 3, 2018
Published for Opposition
Tuesday, September 10, 2019
Abandoned Date
Monday, June 6, 2022

Trademark Owner History
Therasyn Sensors, Inc. - Owner At Publication

Classifications
5 Pharmaceutical preparations for Alzheimer's disease, Parkinson's disease, bacterial infections, viral infections, fungal infections, sepsis, psoriasis, sunburn and thermal injury to skin and underlying tissues, lung disease, asthma, chronic obstructive pulmonary disease (COPD), emphysema, cancer of all types, diabetes, hepatic diseases including hepatitis b or c, hepatic disease including non-alcoholic steatohepatitis (NASH), non-alcoholic fatty liver disease (NAFLD), metabolic syndrome diseases, genetic disorders, Fabry's disease, alpha 1 anti-trypsin deficiency, hemophilia, cystic fibrosis, systemic inflammatory diseases including inflammatory bowel diseases, Crohn's disease, rheumatoid arthritis, Systemic lupus erythematosus (SLE), and ankylosing spondylitis; vaccines and vaccinations to prevent or treat infectious diseases and cancer; drug delivery agents in the form of capsules made of lipids, containing and facilitating the delivery of pharmaceuticals for the treatment of Alzheimer's disease, Parkinson's disease, bacterial infections, viral infections, fungal infections, sepsis, psoriasis, sunburn and thermal injury to skin and underlying tissues, lung disease, asthma, chronic obstructive pulmonary disease (COPD), emphysema, cancer of all types, diabetes, hepatic diseases including hepatitis b or c, hepatic disease including non-alcoholic steatohepatitis (NASH), non-alcoholic fatty liver disease (NAFLD), metabolic syndrome diseases, genetic disorders, Fabry's disease, alpha 1 anti-trypsin deficiency, hemophilia, cystic fibrosis, systemic inflammatory diseases including inflammatory bowel diseases, Crohn's disease, rheumatoid arthritis, Systemic lupus erythematosus (SLE), ankylosing spondylitis; vaccines and vaccinations to prevent or treat infectious diseases and cancer; drug delivery agents in the form of capsules made of cholesteryl ester, containing and facilitating the delivery of pharmaceuticals for use in the treatment of Alzheimer's disease, Parkinson's disease, bacterial infections, viral infections, fungal infections, sepsis, psoriasis, sunburn and thermal injury to skin and underlying tissues, lung disease, asthma, chronic obstructive pulmonary disease (COPD), emphysema, cancer of all types, diabetes, hepatic diseases including hepatitis b or c, hepatic disease including non- alcoholic steatohepatitis (NASH), non-alcoholic fatty liver disease (NAFLD), metabolic syndrome diseases, genetic disorders, Fabry's disease, alpha 1 anti-trypsin deficiency, hemophilia, cystic fibrosis, systemic inflammatory diseases including inflammatory bowel diseases, Crohn's disease, rheumatoid arthritis, Systemic lupus erythematosus (SLE), and ankylosing spondylitis; and vaccines and vaccinations to prevent or treat infectious diseases and cancer

Trademark Events
Jun 6, 2022
Abandonment Notice E-Mailed - No Use Statement Filed
Jun 6, 2022
Abandonment - No Use Statement Filed
Jan 18, 2022
Assigned To Examiner
Nov 6, 2021
Notice Of Approval Of Extension Request E-Mailed
Nov 4, 2021
Sou Extension 4 Granted
Nov 4, 2021
Sou Extension 4 Filed
Nov 4, 2021
Sou Teas Extension Received
Apr 28, 2021
Notice Of Approval Of Extension Request E-Mailed
Apr 26, 2021
Sou Extension 3 Granted
Apr 26, 2021
Sou Extension 3 Filed
Apr 26, 2021
Sou Teas Extension Received
Oct 31, 2020
Notice Of Approval Of Extension Request E-Mailed
Oct 29, 2020
Sou Extension 2 Granted
Oct 29, 2020
Sou Extension 2 Filed
Oct 29, 2020
Sou Teas Extension Received
May 1, 2020
Assigned To Examiner
Apr 21, 2020
Notice Of Approval Of Extension Request E-Mailed
Apr 17, 2020
Sou Extension 1 Granted
Apr 17, 2020
Sou Extension 1 Filed
Apr 17, 2020
Sou Teas Extension Received
Nov 5, 2019
Noa E-Mailed - Sou Required From Applicant
Sep 10, 2019
Official Gazette Publication Confirmation E-Mailed
Sep 10, 2019
Published For Opposition
Aug 21, 2019
Notification Of Notice Of Publication E-Mailed
Aug 4, 2019
Approved For Pub - Principal Register
Jul 29, 2019
Teas/Email Correspondence Entered
Jul 29, 2019
Correspondence Received In Law Office
Jul 23, 2019
Assigned To Lie
Jul 18, 2019
Teas Response To Office Action Received
Jan 22, 2019
Notification Of Non-Final Action E-Mailed
Jan 22, 2019
Non-Final Action E-Mailed
Jan 22, 2019
Non-Final Action Written
Jan 15, 2019
Assigned To Examiner
Oct 12, 2018
New Application Office Supplied Data Entered
Oct 6, 2018
New Application Entered

Trademark Alertz updated from USPTO on 2030-01-24